Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
27th Oct 20174:23 pmRNSTransaction in Own Shares
23rd Oct 20175:38 pmRNSTransaction in Own Shares
20th Oct 20174:30 pmRNSH1 Trading Update
5th Oct 20179:49 amRNSHolding(s) in Company
5th Oct 20179:42 amRNSHolding(s) in Company
5th Oct 20179:39 amRNSHolding(s) in Company
2nd Oct 20176:08 pmRNSHolding(s) in Company
22nd Sep 20177:25 amRNSTransaction in Own Shares
20th Sep 20176:09 pmRNSTransaction in Own Shares
18th Sep 20173:23 pmRNSTransaction in Own Shares
10th Aug 20172:00 pmRNSLaunch of IDS-iSYS
10th Aug 20178:37 amRNSTransaction in Own Shares
9th Aug 20177:00 amRNSTransaction in Own Shares
2nd Aug 20179:30 amRNSDirector/PDMR Shareholding
2nd Aug 20178:33 amRNSHolding(s) in Company
2nd Aug 20178:30 amRNSHolding(s) in Company
27th Jul 20173:45 pmRNSResult of AGM
27th Jul 20178:00 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSAGM Statement
24th Jul 20177:00 amRNSTransaction in Own Shares
3rd Jul 20174:12 pmRNSDirector/PDMR Shareholding
28th Jun 20178:28 amRNSDirector/PDMR Shareholding
22nd Jun 20175:33 pmRNSDirector/PDMR Shareholding
21st Jun 20177:30 amRNSPublication of Annual Report and Accounts
21st Jun 20177:01 amRNSShare Buyback Programme
21st Jun 20177:00 amRNSFinal Results
21st Apr 20177:00 amRNSTrading Update
23rd Mar 20179:14 amRNSDirector/PDMR Shareholding
13th Mar 20178:31 amRNSDirectorate Change
1st Mar 201710:01 amRNSLaunch of IDS-iSYS InaKtif MGP assay
24th Feb 20173:31 pmRNSUpdate on CEO Appointment
7th Feb 20172:46 pmRNSHolding(s) in Company
2nd Feb 20173:14 pmRNSLaunch of IDS-iSYS ACTH assay
26th Jan 20173:05 pmRNSHolding(s) in Company
20th Jan 20174:24 pmRNSDirector Dealing
20th Jan 201710:30 amRNSHolding(s) in Company
19th Jan 20171:12 pmRNSDirectorate Change
18th Jan 201712:26 pmRNSHolding(s) in Company
11th Jan 20173:14 pmRNSDirector/PDMR Shareholding
5th Jan 20175:35 pmRNSHolding(s) in Company
5th Jan 20174:38 pmRNSHolding(s) in Company
25th Nov 20168:00 amRNSHalf-year Report
21st Oct 20167:00 amRNSH1 Trading Update
19th Oct 20167:00 amRNSLaunch of IDS-iSYS Total Testosterone assay
28th Jul 20163:18 pmRNSResult of AGM
28th Jul 20167:00 amRNSAGM Statement
11th Jul 201611:46 amRNSDirector/PDMR Shareholding
5th Jul 201610:07 amRNSDirector/PDMR Shareholding
30th Jun 20166:15 pmRNSDirector/PDMR Shareholding
28th Jun 20166:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.